Ocean Biomedical, Inc. (NASDAQ: OCEA) is a preclinical biotech company focused on moving new therapeutic candidates efficiently from the laboratory to the
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Categories
biopharmaceuticals
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by partnering with
Biogen (BIIB) Q3 2023 Earnings: Key financials and quarterly highlights
Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3%
ABBV Earnings: A snapshot of AbbVie’s Q3 2023 report
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income. The company reported
Ocean Biomedical’s chief scientist Dr. Jonathan Kurtis receives Falk Award for malaria drug candidate
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its chief scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk
Ocean Biomedical (OCEA) announces new patent for anti-fibrosis discovery
Ocean Biomedical, Inc. (NASDAQ: OCEA), a leading biopharma company that works to accelerate the development and commercialization of scientifically compelling assets from
Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
Biopharmaceutical company Ocean Biomedical, Inc. (NASDAQ: OCEA) provided details of its multi-pronged lung cancer program built on novel immunotherapy discoveries by the
Key highlights from Abbott Laboratories (ABT) Q2 2023 earnings results
Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today. Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding
Infographic: Ocean Biomedical Inc. (OCEA) quarter ended September 30, 2022
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here’s a look at the company’s
IPO Alert: What lies ahead for MAIA Biotechnology after stock listing?
The IPO market is yet to fully recover from headwinds like the economic slowdown and Russia-Ukraine war. But activity is gradually picking
ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) Q4 2021 earnings call dated Mar. 15, 2022 Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President and Chief
IPO Alert: Key facts about CinCor Pharma’s upcoming market debut
The healthcare sector, led by pharmaceutical and biotechnology firms, has contributed significantly to the IPO boom that sent the market into overdrive
Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco
Caption: iStock Biofrontera Inc. (Nasdaq: BFRI) is a biopharmaceutical company providing specialty dermatology therapies and services in the United States. Founded in